Overview

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Status:
Recruiting

Trial end date:
2024-02-02

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

Iqvia Pty Ltd